Glenmark Pharmaceuticals Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹3,770.59 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 3.33 per cent from ₹3,900.62 crore. This corresponds to a year-on-year *(YoY) growth of 15.80 per cent.
Operating Profit
Operating Profit stands at ₹389.20 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 43.22 per cent from ₹685.42 crore. This corresponds to a year-on-year *(YoY) growth of 106.80 per cent.
PBDT
PBDT stands at ₹535.67 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 22.19 per cent from ₹688.45 crore. This corresponds to a year-on-year *(YoY) growth of 302.22 per cent.
Profit Before Tax
Profit Before Tax stands at ₹387.76 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 27.39 per cent from ₹534.00 crore. This corresponds to a year-on-year *(YoY) growth of 4,765.24 per cent.
Net Profit
Net Profit stands at ₹301.31 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 25.28 per cent from ₹403.23 crore. This represents a 6,779.22 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Glenmark Pharmaceuticals Ltd News
Glenmark Pharmaceuticals Ltd Earnings
- YOY
- QOQ
Glenmark Pharmaceuticals Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Glenmark Pharmaceuticals Ltd Research Reports
Glenmark Pharmaceuticals Ltd Financial Reports
Glenmark Pharmaceuticals Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Glenmark Pharma. | -2.38% | -0.04% | -1.49% | 2.77% | 4.18% | 21.60% |
| Laurus Labs | -1.48% | 3.23% | 8.26% | 43.41% | 35.26% | 97.66% |
| Biocon | 0.05% | 0.58% | 0.37% | 18.62% | 6.34% | 13.52% |
| Alkem Lab | -0.64% | 2.72% | 6.30% | 5.93% | -0.34% | 14.29% |
| Abbott India | 0.51% | 0.04% | -2.63% | -2.57% | -8.90% | -27.66% |
| Anthem Bioscienc | -0.79% | 0.37% | 1.37% | 15.55% | 16.82% | 4.61% |
| Ipca Labs. | -0.48% | 4.72% | 12.37% | 14.00% | 20.68% | 23.36% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Glenn Saldanha
ED / WTD / Promoter : Cheryl Pinto
ED / President / Global CFO : Anurag Mantri
Non Executive Director : B E Saldanha
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Independent Non Exe. Director : Pradeep Kumar Sinha
Company Sec. & Compli. Officer : Harish Kuber